Dienogest Versus Luteal Phase Fluoxetine in the Management of Premenstrual Syndrome

• Status: Recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

Two hundreds and ten women with premenstrual syndrome will be randomly divided into 3 equal groups using computer generated random numbers. Group 1 will receive oral dienogest (visanne® Bayer, Germany) 2mg for 14 days starting from the 15th day of menstruation, Group 2 will receive fluoxetine (Prozac® Lilly, UK) 20mg and group 3 will receive an oral placebo foe 14 days starting from the 15th day of menstruation.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cairo University
• Treatments: Dienogest; Fluoxetine; Nandrolone

Criteria

Inclusion Criteria:

• PMS

• Consents to the procedure

Exclusion Criteria:

• Previous medical treatment for PMS

• Body mass index > 35 kg/m2

• Irregular periods

• Medical disorders like diabetes, hypertension, cardiac, liver, kidney or heart disease